|
Dr. Allard was formerly Chief Executive Officer, President, and a Director of Biovest International. Prior to joining Biovest, Dr. Allard was Vice President of Medical Affairs of the US affiliate of Sanofi-Synthelabo, a multi-billion dollar global pharmaceutical company and was responsible for the medical strategy of products such as Plavixâ, Ambienâ, Avaproâ, and Eloxatinâ. Dr. Allard served as President of Synthelabo, Inc. and Director of Research and Development at Lorex Pharmaceuticals, where he was responsible for the development of Ambienâ and the start up of Synthelabo, Inc in the US. He led the clinical activities for products such as Ambienâ, Kerloneâ and Uroxatralâ and the liaison efforts with the FDA. He served as European Clinical Director of Clinical Research for Synthelabo (Paris). Dr. Allard received his medical doctorate from Rouen Medical College and received a Diplomate of CESAM (Certificate of Statistical Studies Applied to Medicine) and a PhD in Clinical Pharmacology and Pharmacokinetics (Pitie Salpetriere Hosp.); Paris, France. | 